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ABSTRACT
The Androgen Receptor (AR) is a key molecule in the development, maintenance 
and progression of prostate cancer (PC). However, the relationship between the AR 
and co-regulatory proteins that facilitate AR activity in castrate resistant settings 
remain understudied. Here we show that protein phosphatase 1 regulatory subunits, 
identified from a phosphatase RNAi screen, direct PP1 catalytic subunits to a varied 
yet significant response in AR function. As such, we have characterised the PP1β 
holoenzyme, myosin phosphatase (MLCP), as a novel ligand independent regulator 
of the AR. Sustained MLCP activity through down-regulation of the MLCP inhibitory 
subunit, PPP1R14C, results in impaired AR nuclear translocation, protein stability 
and transcriptional activity in distinct models of PC progression, culminating in 
restoration of a non-malignant prostate genotype. Phenotypically, a marked reduction 
in cell proliferation and migration, characterised by G1 cell cycle arrest is observed, 
confirming PP1 holoenzyme disruption as a novel treatment approach in PC.
INTRODUCTION
Prostate cancer (PC) is the most common non-
cutaneous cancer in males in western countries and is fast 
emerging as a significant health risk in the developing 
world, accounting for the second highest rate of cancer 
related deaths in men worldwide (www.cancerresearch.
co.uk). Androgen deprivation therapy (ADT), aimed 
at disrupting the androgen signalling axis, is initially 
successful [1], with the vast majority of patients 
demonstrating tumour regression. Unfortunately, up to 
95% of patients relapse within a median time of 2 years 
[2], with disease progressing to an androgen-independent 
state termed castrate resistant PC (CRPC), characterised 
by increased incidence of metastasis and ultimately 
death. However, it has become increasingly evident that 
the androgen receptor (AR) is still capable of driving 
disease progression through re-activation of the androgen 
signalling axis, and as such remains a viable therapeutic 
target [3]. Numerous routes to resistance have been 
described thus far including AR gene amplification [4], 
the acquisition of AR somatic mutations and emergence of 
receptor splice variants [5].
AR activity is regulated at numerous levels by the 
activity of co-activator and co-repressor proteins [6] and 
uncontrolled activity of a number of these co-regulators has 
been postulated to enable progression to CRPC [7–9]. To 
date, the impact of protein kinases on AR function has been 
extensively studied (reviewed in [10]), with modulation of 
AR activity via the inhibition of upstream kinases including 
Aurora A [11], CDK1 [12] and MAPK [13], representing 
proven examples that AR co-activator inhibition may 
represent a viable therapeutic approach in PC and CRPC. 
In contrast, the opposing activity of dephosphorylation, 
performed by phosphatase enzymes, is markedly 
understudied, with only a limited number of phosphatases 
described as being capable of modulating AR activity. 
Recent literature has implicated protein phosphatase 1α 
(PP1α) as an AR co-activator capable of promoting AR 
stability, nuclear localization and transcriptional potency, 
but to date has displayed little therapeutic potential due 
to the toxic nature of current inhibitors targeting the 
PP1 catalytic subunits [14–16]. However, PP1 catalytic 
subunits do not exist as a monomeric subunits in-vivo, but 
rather, associate with a wide range of mutually exclusive 
regulatory subunits to form PP1 holoenzymes; each with 
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distinct substrate specificities, subcellular localizations, 
and catalytic activities [17]. This provides the PP1 catalytic 
subunit with a dynamic means of counteracting the highly 
specific and sensitive action of hundreds of kinases. 
Myosin Phosphatase (MLCP) is one such PP1 holoenzyme, 
comprising the PP1β catalytic subunit, PPP1R12A 
regulatory subunit, and a small 20 kDa protein of unknown 
function to form a heterotrimeric complex [18, 19]. 
PPP1R12A acts as a regulatory subunit to PP1β by binding 
to a highly specific subset of PP1 substrates, and bringing 
the substrate and catalytic subunit into contact. As its 
name would suggest, MLCP effectively dephosphorylates 
phosphorylated myosin regulatory light chain (MLC), and 
as such plays a pivotal role in actomyosin contractility. 
However, a broad range of signalling molecules have 
subsequently been identified as substrates for MLCP, 
including RB1, NF2, PLK1, HDAC7 and tau [20–25]. 
Interestingly, MLCP activity can be potently inhibited 
following association of the MLCP complex with one of 
the PPP1R14 family of MLCP inhibitory proteins, that 
upon phosphorylation behave as pseudosubstrates for this 
specific PP1 holoenzyme [26–28]. 
Through the implementation of a human phosphatome 
RNAi screen we demonstrate for the first time that the 
PP1b catalytic subunit is repressive towards AR function, 
but more specifically, that the impact of PP1 activity on AR 
function is entirely dependent upon the association of the 
catalytic subunit with its respective regulatory subunits. 
As such, we characterise the PP1β holoenzyme MLCP 
as a novel dynamic regulator of the AR, and demonstrate 
that through downregulation of the endogenous MLCP 
regulatory inhibitory subunit, PPP1R14C [28], ligand 
induced AR nuclear translocation, stability, and ultimately 
AR transcriptional activity is significantly reduced in 
distinct PC cell line models representing both androgen 
sensitivity and castration resistance. Phenotypically we 
are able to show that depletion of PPP1R14C reduces PC 
cell growth and migration characterised by G1 cell cycle 
arrest. Conversely, depletion of PPP1R12A results in 
increased AR mRNA expression, protein expression and 
AR transcriptional activity in both the presence and absence 
of androgen, confirming MLCP as a novel dynamic ligand 
independent regulator of the AR. With this in mind, we 
propose that the disruption of specific PP1 holoenzymes 
provides a distinct route of PP1 inhibition, and as such, a 
viable approach in the treatment of PC and CRPC. 
RESULTS
Human phosphatome RNAi screen reveals 
distinct roles for protein phosphatase 1 
regulatory subunits in the regulation of 
androgen receptor activity
Post-translational modifications of the AR have 
been widely studied to investigate the functional interplay 
between the AR and co-activators or co-repressors 
for therapeutic benefit (reviewed [29]). However, we 
identified a significant knowledge gap in the role of 
phosphatase enzymes in AR regulation. In order to address 
this we performed an RNAi screen individually targeting 
291 phosphatase enzymes and phosphatase associated 
proteins, and assessed the impact on AR transcriptional 
activity using a derivative of the androgen-responsive 
cell line LNCaP that stably over-expresses luciferase 
under the control of the PSA gene promoter (termed 
LNCaP-PSALuc). Figure 1A depicts the impact of target 
knockdown (mean, n = 3) on luciferase activity, used as a 
surrogate for AR activity (detailed luciferase activity for 
all 291 targets can be found in Supplementary Table 1). 
RNAi depletion of the AR and previously identified 
AR regulators Figure 1B, including PP1a and PP2A 
Figure 1C, yielded the expected outcome in terms of 
AR activity, thus validating the results of the screen with 
known research [15, 16, 30, 31]. Interestingly, depletion 
of the PP1b catalytic subunit significantly reduced AR 
transcriptional activity, suggesting a contrasting role in AR 
regulation to the closely related PP1a subunit. However, 
it became clear that RNAi knockdown of PP1 regulatory 
subunits resulted in distinct, yet highly significant, 
modulation of AR activity, revealing a more complex 
role for PP1 holoenzymes in the regulation of AR activity 
than previously described (Figure 1D). Furthermore, 
PP1 regulatory subunits accounted for 17.5% of the 
most significant AR stimulatory factors (n = 13/75). As 
previous research has implemented RNAi depletion or 
small molecule inhibition of the PP1 catalytic subunits 
in AR activity studies, eliminating the full repertoire of 
PP1 holoenzymes, we sought to characterise the individual 
roles of regulatory subunits on AR function. This approach 
would enable our research to elucidate the specific PP1 
holoenzymes responsible for the observed impacts on AR 
activity.
Components of the PP1β holoenzyme myosin 
phosphatase are dysregulated in human prostate 
cancer 
We evaluated the expression of PP1 regulatory 
subunits in publicly available prostate cancer datasets. 
Whilst evidence existed for inter-patient variation in the 
expression of the PP1 regulatory subunit cohort, it became 
apparent that two components of the PP1β holoenzyme 
MLCP were consistently dysregulated in multiple datasets 
analysed (Figure 2 [32–35]). PPP1R12A, the substrate 
specifying subunit for MLCP, was identified as being 
down-regulated in PC vs matched normal prostate, but 
more specifically, down-regulated at sites of metastasis 
vs primary tumours and matched normal prostate. 
Conversely, PPP1R14C, an inhibitory subunit for MLCP, 
was found to be up-regulated in PC vs matched normal 
prostate, particularly at metastatic sites. Interestingly, 
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these expression trends occurred both independently and 
combined. As PPP1R14C is a negative regulator of MLCP 
activity at the post-translational level, this data would 
suggest a net loss of MLCP activity exists throughout the 
emergence and progression of PC to metastatic PC. Here, 
PPP1R14C and PPP1R12A were identified as novel AR 
activators and repressors in our phosphatase RNAi screen 
respectively. As previously mentioned, regulation of the 
PP1 catalytic subunits relies upon the dynamic association 
with their respective regulatory subunits, and as such exist 
as up to 200 distinct holoenzymes [36]. In this instance, 
PPP1R12A provides substrate specificity to the PP1b 
catalytic subunit, forming the holoenzyme MLCP. Indeed, 
two recent independent research articles have identified 
miR-30d as a prognostic marker in PC, conferring 
enhanced proliferation, invasion and significantly shorter 
time to biochemical recurrence [37, 38]. Interestingly, 
PPP1R12A has been identified as the direct target of 
miR-30D. Similarly, a novel oncogenic pathway has 
recently been described in invasive lobular breast cancer, 
whereby truncating mutations in PPP1R12A promote 
the malignant transformation of E-cadherin deficient 
mammary epithelial cells by impairing the ability of 
MLCP to effectively dephosphorylate its substrates [39]. 
In addition to genomic and transcriptional events, the 
activity of MLCP can be modulated post-translationally 
upon association with the highly specific MLCP inhibitory 
PPP1R14 family of subunits. PPP1R14A-D family 
members are not intrinsically inhibitory towards MLCP, 
but upon phosphorylation by a number of kinases, become 
potent inhibitory pseudosubstrates specific to MLCP 
following a 600–1000 fold increase in their affinity for 
the MLCP complex. Indeed, PPP1R14A is overexpressed 
in a number of human malignancies, and it has been 
demonstrated that increased expression of PPP1R14A 
is sufficient to induce tumorigenic transformation in 
multiple cell lines, characterised by a reduction in MLCP 
activity [22]. Similarly, PPP1R14B has been reported to 
be overexpressed in ovarian clear cell carcinoma [40], 
as well as serving as an unfavourable prognostic marker 
in liver and pancreatic cancers. Furthermore, we also 
observe significant overexpression of PPP1R14B in 
human prostate cancer following interrogation of publicly 
available datasets. 
Depletion of PPP1R14C reduces AR 
transcriptional activity in distinct cell line 
models of prostate cancer
Data obtained from the phosphatase RNAi screen 
in LNCaP-PSALuc cells suggested that PPP1R14C 
depletion reduced AR transcriptional activity by 60%. To 
confirm this, PPP1R14C was knocked down in several 
additional PC cell line models representing different levels 
of androgen sensitivity. As knockdown of PPP1R14C 
with 3 independent RNAi oligos resulted in significant 
repression of both PPP1R14C and AR target gene mRNA 
expression in LNCaP cells (Supplementary Figure 1), 
siPPP1R14C-1 was taken forward for future assays. 
Furthermore, due to a lack of commercial antibodies 
available for PPP1R14C, enhanced activity of MLCP 
towards its substrate phosphorylated myosin has been used 
as a surrogate for PPP1R14C depletion at the protein level. 
PPP1R14C depletion in parental LNCaP cells significantly 
Figure 1: Phosphatase regulatory subunits differentially impact upon AR activity. (A) Impact of phosphatase depletion 
on AR transcriptional activity. AR activity represents mean luciferase activity (Fold-Change, n = 3). Full dataset (281 targets) found in 
Supplementary Table 1. (B) Impact of AR and previously identified AR modulating phosphatase depletion on AR transcriptional activity. 
(C) Impact of protein phosphatase catalytic subunit depletion on AR transcriptional activity. (D) Impact of protein phosphatase regulatory 
subunit depletion on AR transcriptional activity.
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reduced AR transcriptional activity as indicated by down-
regulation of receptor target genes PSA, TMPRSS2 and 
KLK2 (Figures 3A and 3B). Furthermore, it is possible 
to demonstrate that PPP1R14C RNAi knockdown results 
in reduced AR protein expression when compared to the 
scrambled control, as depicted in Figure 3C. Critically, 
AR protein expression and activity was compromised by 
PPP1R14C depletion in both the presence and absence 
of dihydrotestosterone (DHT), suggesting that MLCP 
modulates AR function in a ligand independent manner. 
Next we investigated the impact of PPP1R14C 
depletion in the VCaP CRPC cell line. Similarly, we 
were able to demonstrate that depletion of PPP1R14C 
is capable of significantly repressing AR transcriptional 
activity in both the presence and absence of androgen as 
depicted in Supplementary Figure 2. The emergence of AR 
splice variants is a clinically relevant treatment resistance 
mechanism [41], and in order to assess the impact of 
PPP1R14C on AR-V activity, VCaP cells underwent 
PPP1R14C manipulation in the presence of 10mM 
enzalutamide which specifically targets full length, ligand 
binding domain-containing AR. Crucially, we were able 
to show that AR activity was diminished following RNAi 
depletion of PPP1R14C (Figure 3D), consistent with 
the notion that MLCP is a ligand independent regulator 
of the AR, and that MLCP activity is also repressive to 
constitutively active AR splice variants. The impact of 
PPP1R14C depletion on AR transcriptional activity in 
Figure 2: Myosin phosphatase components are dysregulated in prostate cancer. Expression of PPP1R14C and PPP1R12A is 
evaluated in 4 publicly available prostate cancer datasets.
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VCaPs correlates with a reduction in the steady state 
protein levels of full length AR and splice variant AR, 
as observed in Figure 3E. Finally, to further confirm 
that MLCP may be capable of repressing aberrant AR 
activity, PPP1R14C RNAi depletion was performed 
in an enzalutamide resistant LNCaP cell line (LNCaP-
EnzR), generated in house, that maintains an active, 
and responsive, androgen signalling axis in the presence 
of this particular anti-androgen. Crucially, significant 
repression of AR target gene expression was observed 
upon knockdown of PPP1R14C in the presence of 10 mM 
enzalutamide supporting the concept that the liganded and 
unliganded full-length AR, as well as AR-Vs, are regulated 
by the PPP1R14C-MLCP axis, and provides evidence that 
PPP1R14C modulation may be a viable therapeutic target 
for treatment of advanced CRPC (Figure 3F and 3G). 
To investigate the impact of diminished MLCP 
activity on AR function, PPP1R12A was depleted by 
RNAi. Crucially, in LNCaP cells we demonstrate a 
significant increase in AR mRNA and protein expression 
following PPP1R12A depletion in both the presence 
and absence of androgen, culminating with significantly 
increased AR transcriptional activity (Figure 3H, 3I, 3J and 
Supplementary Figure 3). Indeed, what is most surprising 
is that the increases in AR expression and activity are most 
pronounced in the absence of androgen, suggesting MLCP 
inhibition may serve as a route to castration resistance. 
Furthermore, we are able to demonstrate that PPP1R12A 
RNAi depletion in VCaP cells results in increased protein 
expression of both full-length and splice variant AR 
(Figure 3K).
PPP1R14C depletion prevents ligand induced 
AR nuclear translocation and promotes AKT 
mediated proteasomal degradation
To gain a better understanding of how PPP1R14C 
depletion impacts on the molecular functionality of the 
Figure 3: PPP1R14C RNAi depletion reduces AR transcriptional activity in distinct cell line models of prostate cancer. 
(A–B) Impact of PPP1R14C RNAi depletion on PSA, TMPRSS2, KLK2 and AR gene expression in LNCaP cells cultured in steroid depleted 
media ± 10 nM DHT. (C) Western blot analysis of AR and pMLC20 following PPP1R14C RNAi depletion in LNCaP cells in the presence 
and absence of androgen. (D) Impact of PPP1R14C RNAi depletion on PSA, TMPRSS2, KLK2, full-length AR and AR-V gene expression 
in VCaP cells cultured in full media supplemented with 10 µM enzalutamide. (E) Western blot analysis of AR and pMLC20 following 
PPP1R14C RNAi depletion in VCaP cells in the presence of 10 µM enzalutamide. (F) Impact of PPP1R14C RNAi depletion on PSA, 
TMPRSS2, KLK2 and AR gene expression in LNCaP-EnzR cells cultured in full media supplemented with 10 µM enzalutamide. (G) Western 
blot analysis of AR and pMLC20 following PPP1R14C RNAi depletion in LNCaP-EnzR cells in the presence of 10µM enzalutamide. (H) 
Impact of PPP1R12A RNAi depletion in LNCaP cells in the absence of androgen. (I–J) Western blot analysis of PPP1R12A and AR 
following PPP1R12A RNAi depletion in LNCaP cells in the presence and absence of androgen. (K) Wetern blot analysis of PPP1R12A and 
AR following PPP1R12A RNAi depletion in VCaP cells in full media. Data represents 3 independent experiments ± SEM. P- values were 
determined by unpaired student t test (**, * denote P-values of < 0.001 and < 0.01 respectively). 
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AR, we interrogated the phosphorylation status of the 
AR in LNCaP cells depleted of PPP1R14C (Figure 4A). 
Crucially, a dramatic reduction in AR S81 phosphorylation 
is observed in PPP1R14C knockdown cells compared to 
the scrambled control. This phospho-residue has been 
extensively studied in relation to AR activity [42, 43], 
and has been shown to correlate with increased nuclear 
localization and enhanced transcriptional activity. 
Similarly, a reduction in the phosphorylation of S515 is 
observed following PPP1R14C depletion. Whilst this 
site lies within a known MAPK consensus sequence 
[44], more recent investigations have demonstrated a 
correlation between increased phosphorylation and CDK1 
activity [45], with phosphorylation being associated with 
enhanced AR activity and disease progression, particularly 
in the absence of androgen. To confirm the functional 
impact of the reduced AR phosphorylation at these sites 
we performed nuclear/cytoplasmic fractionation of 
LNCaP cells depleted of PPP1R14C following androgen 
stimulation to investigate the subcellular localization of 
the AR. Indeed, as depicted in Figure 4B, almost complete 
ablation of nuclear AR is observed in the absence of 
PPP1R14C compared to the scrambled control. Finally, a 
site associated with repression of AR activity [43, 46–48], 
S213, was found to be significantly enhanced. 
Phosphorylation of this residue is mediated by AKT and 
PIM-1, which leads to the subsequent recruitment and 
ubiquitylation of the AR by MDM2, culminating in AR 
proteasomal degradation. Further to our previous findings 
of reduced steady state AR protein levels, knockdown 
of PPP1R14C in the presence of cycloheximide 
(CHX) results in accelerated proteasomal degradation 
compared to the scrambled control (Figure 4C), but more 
specifically, AR transcriptional activity can be partially 
rescued following PPP1R14C depletion via exposure to 
both the proteasomal inhibitor MG132 (Supplementary 
Figure 4) and the AKT inhibitor MK2206 (Figure 4D).
RNA sequencing following PPP1R14C RNAi 
knockdown reveals activation of clinically 
relevant tumour suppressors and the partial 
restoration of a non-malignant genotype
To gain a greater insight into the role of MLCP 
on AR signalling we obtained a global gene expression 
signature by performing RNA sequencing following 
PPP1R14C RNAi knockdown in the LNCaP cell line in 
the presence of 10 nM DHT (Figure 5A). Data analysis 
and subsequent gene set enrichment analysis (GSEA, 
MSigDB, Broad Institute [49]) revealed that 826 genes 
were differentially expressed ± 2-fold compared to the 
scrambled control, including significant repression of 
the hallmark androgen response pathway (Figure 5B, 
n = 101, NES -2.9946, p < 0.001). Furthermore, no 
evidence arose to suggest alteration of additional nuclear 
hormone receptor activity, e.g. Glucocorticoid receptor. 
Interestingly, genes involved in cell cycle (Figure 5C, 
n = 421, NES -8–8425, p < 0.001), in particular G1-S 
transition (Supplementary Figure 5, n = 112, NES -6.0567, 
p < 0.001), were negatively enriched following PPP1R14C 
depletion. Confirmation of this impact by FACS analysis 
revealed that PPP1R14C depletion in LNCaP cells leads to 
significant G1 cell cycle arrest compared to the scrambled 
control (Figure 5D, mean ± sem, 69 ± 1.22% vs. 84 ± 
0.46%, p-value < 0.05). 
As previously established, depletion of PPP1R14C 
is capable of enhancing the activity of MLCP towards 
its substrates. Consistent with recent reports that MLCP 
is capable of dephosphorylating RB1 at the inhibitory 
phospho-residues serine 807 and serine 811 [20, 21], we 
show a reduction in RB1 phosphorylation at residues 
S809/S811 by immunoblot following PPP1R14C 
depletion (Figure 5E). As expected, hypophosphorylation 
of RB1 at S807/811 results in significant repression in the 
expression of E2F1 target genes (Figure 5F, n = 200, NES 
-9.3259, p < 0.001), providing mechanistic evidence to 
support the G1 cell cycle arrest observed in Figure 5D. 
Most importantly, however, genes identified as being 
significantly up-regulated in PC tissue vs. matched normal 
prostate tissue in 5 independent genomic studies [34, 
50–53], were found to be negatively enriched in LNCaP 
cells depleted of PPP1R14C compared to LNCaP cells 
treated with the scrambled control. Conversely, genes 
found to be significantly down-regulated in PC tissue vs 
matched normal prostate tissue were found to be positively 
enriched upon knockdown of PPP1R14C vs Scrambled 
siRNA (Figure 5G). This would suggest that it may be 
possible to partially restore a non-malignant transcriptome 
through enhanced myosin phosphatase activity, and more 
specifically, through downregulation of PPP1R14C.
Enhancing myosin phosphatase activity is a 
viable therapeutic approach in distinct models of 
PC disease progression
As our previous studies have identified significant 
repression of AR transcriptional activity and G1 cell cycle 
arrest, we sought to further characterise the phenotypic 
impact of enhanced MLCP activity in distinct PC cell line 
models. To address this we measured cell growth, using 
live cell imaging, following manipulation of PPP1R14C 
expression (Figure 6A). Consistent with a role for 
PPP1R14C as regulator of AR transcriptional activity and 
G1-S transition, depletion of PPP1R14C in LNCaP cells 
results in significant repression of cell growth. Similarly, 
knockdown of PPP1R14C in VCaP cells in the presence 
of enzalutamide results in a pronounced reduction 
in cell growth. Finally, knockdown of PPP1R14C in 
enzalutamide-resistant LNCaP cells results in significant 
impairment of cell growth, further confirming the 
regulatory mechanism imposed by the MLCP-PPP1R14C 
axis on AR is ligand independent, and as such exploitable 
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Figure 4: PPP1R14C RNAi depletion prevents cell cycle associated AR phosphorylation, reducing the proliferative 
and migratory capacity of prostate cancer cells. (A) Western blot analysis of AR phosphorylation status at S81, S213 and S515 
following AR immunoprecipitation in LNCaP cells depleted of PPP1R14C. (B) Nuclear-cytoplasmic localization as determined by western 
blot following nuclear-cytoplasmic fractionation of LNCaP cells depleted of PPP1R14C. (C) Western blot analysis of AR protein expression 
following PPP1R14C RNAi depletion in LNCaP cells cultured in full media and subsequently incubated with 20 µg/ml cycolheximide. (D) 
Impact of AKT inhibition (1 µM MK2206) on PSA mRNA expression in LNCaP cells cultured in full media and depleted of PPP1R14C. 
Data represents 3 independent experiments ± SEM. P- values were determined by unpaired student t test (**, * denote P-values of < 0.001 
and < 0.01 respectively). 
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irrespective of anti-androgen resistance. Furthermore, the 
clinical expression of MLCP components could suggest 
diminished MLCP activity may play a role in tumour 
metastasis, and as such we sought to investigate the role of 
PPP1R14C in cell migration. Employment of the boyden 
chamber assay went on to prove that PPP1R14C depletion 
results in significant repression of LNCaP cell migration 
compared to the scrambled control (Figure 6B), providing 
compelling evidence that PPP1R14C represents a viable 
therapeutic target in the treatment of both PC and CRPC.
DISCUSSION
Recent evidence has highlighted the continued 
benefit of targeting the AR in the treatment of PC under 
castrate resistant settings [54]. However, it is crucial 
we develop a greater understanding of the molecular 
mechanisms underlying the AR signalling axis, 
particularly in the absence of androgens, to develop novel 
therapeutic strategies for treatment-resistant patients. It 
is also becoming increasingly apparent that advanced PC 
patients harbour complex and heterogenous aberrations 
of AR co-activators and repressors [55], contributing to 
AR signalling and treatment resistance. PP1a is one such 
co-regulator linked to increased AR stability, localization 
and transcriptional activity, with more recent literature 
demonstrating continued AR co-activation in castrate 
resistant settings and activation of AR splice variants. 
However, here we identify a contrasting role with the 
activity of the PP1β catalytic subunit in AR regulation, and 
furthermore, demonstrate for the first time that through 
association with its regulatory subunits, PP1 imposes 
both activation and repression of the AR signalling 
cascade of varying magnitudes in a PP1 holoenzyme 
specific manner. In addition, we have identified two 
subunits from the same PP1β holoenzyme complex, 
MLCP, capable of reciprocally modulating AR function 
in a dynamic ligand-independent manner. This raises the 
possibility of modulating the interaction between PP1 
and its regulatory subunits as a means of therapeutically 
targeting PP1 activity in a selective manner. Indeed, 
disruption of specific PP1 holoenzymes is an approach 
recently explored by Tsaytler et al to restore proteostasis 
in a number of human conditions [56, 57]. 
Our key findings, schematically summarised in 
Figure 7, demonstrate that MLCP is a dynamic regulator 
Figure 5: PPP1R14C RNAi depletion partially restores a non-malignant prostate genotype. (A) Volcano plot representing 
the differential gene expression quantified by RNA-seq following RNAi depletion of PPP1R14C in LNCaP cells cultured in steroid depleted 
media supplemented with 10 nM DHT. (B–C) GSEA of the PPP1R14C RNAi gene expression profile demonstrates significant and negative 
enrichment of genes associated with the Hallmark_Androgen_Response geneset(curated geneset derived from 8 independent studies 
investigating androgen responsive genes) and the Reactome_Cell_Cycle gene set, respectively. (D) Representative example of cell cycle 
analysis of LNCaP cells depleted of PPP1R14C as quantified by PI flow cytometry. (E) Western blot analysis of total RB1, pRB1 S807/811 
and E2F1 protein expression following PPP1R14C depletion in LNCaP cells cultured in full media. (F) GSEA of the PPP1R14C RNAi gene 
expression profile demonstrates significant and negative enrichment of genes associated with the Hallmark_E2F_Targets geneset (curated 
geneset derived from 6 independent studies investigating E2F transcription factor target genes). (G) GSEA of the PPP1R14C RNAi gene 
expression profile with 5 independent studies investigating differential gene expression of PC samples vs matched paired normal prostate 
tissue. Figure displays geneset size and normalised enrichment score. 
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Figure 6: PPP1R14C RNAi depletion significantly impairs prostate cancer cell growth and migration. (A) Impact of 
PPP1R14C RNAi depletion on LNCaP, VCaP and LNCaP-EnzR cell growth as quantified by live cell imaging (IncucyteZoom, Essen 
Bioscience). Cell confluence was measured as a percentage every 6 hours over a 96 hour period with subsequent data represented as fold-
change from the scrambled RNAi control. Data represents 3 independent experiments ± SEM. P-values were determined by TWO-way 
ANOVA using Turkey’s comparison test (**, * represents < 0.001 and < 0.01 respectively). (B) Impact of PPP1R14C RNAi depletion on LNCaP 
cell migration was measured using boyden chamber assays and compared to the scrambled RNAi control. Data represents 3 independent 
experiments ± SEM. ONE-way ANOVA statistical analysis was performed to test statistical significance (* represents a P-value < 0.0001).
Figure 7: Myosin phosphatase is a dynamic ligand-independent regulator of AR function. Schematic summary of MLCP 
activity on the AR signaling axis. Depletion of the MLCP inhibitory subunit PPP1R14C results in sustained MLCP activity towards its 
substrates. Amongst these, RB1 is maintained in a hypophosphorylated state, which represses E2F1 mediated cell cycle progression and 
the associated AR phosphorylation events by CDKs. This leads to enhanced AKT mediated proteasomal degradation of the AR culminating 
in significant repression of AR target gene expression. Phenotypically this reduces cell cycle progression, proliferation and migration. 
Conversely, depletion of the MLCP substrate specifying subunit PPP1R12A, representative of MLCP inhibition, results in enhanced AR 
gene and protein expression and subsequent target gene expression.
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of AR function in both androgenic and castrate settings, as 
well as in PC cell lines resistant to current anti-androgens. 
Crucially, we show that inhibition of PPP1R12A, the 
substrate specifying subunit for MLCP, significantly 
increases AR mRNA and protein expression in the 
absence of androgen, resulting in enhanced AR regulated 
gene expression. Therefore, repression of MLCP activity 
under castrate conditions provides a viable route for PC 
cells to overcome diminished intratumoral androgen 
concentrations or direct AR antagonism. Indeed, we 
have identified increased expression of MLCP inhibitory 
subunits, in combination with reduced PPP1R12A 
expression in clinical datasets. Furthermore, downstream 
substrates of MLCP, such as RB1 and PLK1 [58, 59], 
have been implicated in PC disease progression and 
treatment resistance, and as such have been identified as 
significant prognostic markers. Here we show that MLCP 
modulation provides a plausible route of repressing AR 
function, whilst enhancing dephosphorylation of crucial 
downstream molecules including RB1, and as such 
provides a novel therapeutic approach for targeting AR 
signalling and aberrant cell cycle machinery in PC and 
CRPC. 
MATERIALS AND METHODS
Contact for reagent and resource sharing
Further information and requests for resources and 
reagents should be directed to and will be fulfilled by the 
Lead Contact, James Grey (james.grey2@ncl.ac.uk).
Method details
Cell culture
All cells were maintained in RPMI-1640 (Sigma 
Aldrich) supplemented with 10% (v/v) foetal bovine 
serum (Sigma Aldrich) and 2 mM L-glutamine (Sigma 
Aldrich) at 37°C. For steroid-depleted conditions, cells 
were grown in RPMI-1640 supplemented with 10% (v/v) 
dextran-coated charcoal-stripped foetal bovine serum 
(HyClone) and 2 mM L-glutamine. LNCaP-EnzR cells 
were maintained in the presence of 10 mM enzalutamide. 
Human phosphatase RNAi screen
Using an automated robot (EpMotion 5070, 
Eppendorf), 3 independent RNAi oligos targeting 291 
phosphatases and 15 control targets were aliquoted into 96 
well plates with a final RNAi concentration of 25 nM and 
stored at –80°C. Prior to the reverse transfection of cells, 
RNA iMAX (Invitrogen) was incubated with the RNAi 
for 30 minutes. Then, 5000 LNCaP-PSALuc in DCC 
media were added to the plates and cultured for 24 hours 
prior to the addition of 1 mM DHT. Following 48 hours 
DHT stimulation, 25 µl luciferin reagent (Steady-Glo, 
Promega) was added to each well prior to luminescence 
quantification using a FLUOstar Omega plate reader 
(BMG Labtech). RNAi depletion of each phosphatase 
target was performed in triplicate, with subsequent target 
identification validated by qPCR analysis.
RNAi transfection, RNA extraction and qPCR
Transient RNAi transfections were carried out using 
RNA iMAX (Invitrogen) according to manufacturer’s 
protocol for a total of 72 hours. RNA was then extracted 
as previously described [8], quantified using a Nanodrop 
(ThermoFisher) and reverse transcribed using MMLV 
Reverse Transcriptase (Promega). Target gene expression 
was evaluated by qPCR using the synthesised cDNA, 
required primers, SYBR Green (Promega) on an Applied 
Biosystems 7900HT system.
SDS-PAGE and western blotting
Cell lysis and western blot analysis was performed 
as previously described [7].
Cell proliferation, migration and flow cytometry analysis
Cell confluency was measured using the Incucyte 
Zoom live cell imager (Essen Bioscience) as a surrogate 
for cell growth over a 96-hour period. Images were 
collected from various fields every 4 hours, with subsequent 
confluency data normalised to 0-hour time-point and 
presented as fold-change. Boyden chamber assays were 
employed to investigate cell migration as previously 
described [60] following RNAi depletion of PPP1R14C 
for 48 hours. Positively migrated cells were fixed, stained, 
and quantified by eye. Cells within 12 fields of view were 
quantified for each technical repeat within each experimental 
repeat (n = 3). Flow cytometry was employed to investigate 
the cell cycle profile of LNCaP cells. Cells were depleted of 
PPP1R14C for 72 hours prior to preparation and staining with 
propridium iodide as previously described [61]. Propridium 
iodide staining was detected using a FACSCalibur (BD 
Biosciences). Data is mean % of cells from 3 technical 
repeats, representative of one experimental repeat from a 
collection of 3 independent experiments.
RNA sequencing
LNCaP cells were subject to PPP1R14C RNAi 
depletion as previously described for a total of 72 hours, 
including a 24 hour 10 nM DHT stimulation following a 
48-hour incubation in steroid depleted conditions. RNA 
was extracted with RNeasy Plus Kit extraction columns 
(Qiagen) and quantified with a Nanodrop (ThermoFisher). 
RNA integrity was calculated through the use of a 2100 
Bioanalyzer (Agilent Technologies). Only samples possessing 
a RIN value > 9 were taken forwarded for [62] sequencing 
(Non-silencing and siPPP1R14C, n = 3). RNA samples 
were prepared using Stranded Total RNA Sample Prep Kit 
(Illumina), depleted of ribosomal RNA using the Ribozero 
Gold Kit (Illumina) and sequenced with 100 bp paired end 
reads (~80 million reads/sample) on an Illumina HiSeq 2500 
platform. Reads were mapped to human genome hg19 using 
Oncotarget3932www.impactjournals.com/oncotarget
STAR [63]. Raw read counts were calculated using HTseq 
[64] prior to differential gene expression analysis with 
DEseq2. Gene expression analysis was peformed using the 
gene set enrichment analysis software (Broad Institute) and 
publicly available datasets from the molecular signatures 
database (MSigDB, Broad Institute).
Quantification and statistical analysis
Statistical analysis was performed using GraphPad 
Prism V7.0. Unless otherwise specified, data are presented 
as mean ± SEM. Comparisons were performed with the 
stated statistical tests whose values are represented in the 
figure legends.
Data and software availability
siPPP1R14C RNAseq data to be deposited in GEO. 
All key resources including qPCR sequences, antibodies, 
RNAi sequences and small molecule reagents can be 
found in the Supplementary Table 1.
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